FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Carlos Dujovne

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Carlos A Dujovne; Craig D Williams; Matthew K Ito
What combination therapy with a statin, if any, would you recommend?
Maureen Mays; Carlos A Dujovne
Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?
Harold E Bays; Carlos A Dujovne
Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Carlos Dujovne (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Carlos A Dujovne; Craig D Williams; Matthew K Ito
What combination therapy with a statin, if any, would you recommend?
Current atherosclerosis reports 2011;13(1):12-22.
2008: Maureen Mays; Carlos A Dujovne
Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?
Current atherosclerosis reports 2008;10(1):45-52.
2006: Harold E Bays; Carlos A Dujovne
Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.
Current atherosclerosis reports 2006;8(2):144-56.
2003: Michael H Davidson; Leiv Ose; Jiri Frohlich; Russell S Scott; Carlos A Dujovne; Ivan D Escobar; Marcelo C Bertolami; Frank Cihon; Darbie Maccubbin; Michele Mercuri
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Clinical cardiology 2003;26(11):509-14.
2003: Harold E Bays; James M McKenney; Carlos A Dujovne; Helmut Schrott; Michael J Zema; Jack Nyberg; Diane E MacDougall
Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
The American journal of cardiology 2003;92(5):538-43.
2003: Robert H Knopp; Carlos A Dujovne; A Le Beaut; Leslie Lipka; Ramachandran Suresh; Enrico Veltri
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.
International journal of clinical practice 2003;57(5):363-8.
2003: Harold E Bays; Carlos A Dujovne
Colesevelam HCl: a non-systemic lipid-altering drug.
Expert opinion on pharmacotherapy 2003;4(5):779-90.
2003: Harold E Bays; Carlos A Dujovne; Mark E McGovern; T Eric White; Moti L Kashyap; A Gene Hutcheson; John R Crouse
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
The American journal of cardiology 2003;91(6):667-72.
2003: Jonathan L Isaacsohn; Donald B Hunninghake; Helmut Schrott; Carlos A Dujovne; Robert Knopp; Stuart R Weiss; Harold E Bays; John R Crouse; Michael H Davidson; Leonard M Keilson; James McKenney; Stanley G Korenman; Adrian S Dobs; Evan Stein; Ronald M Krauss; Darbie Maccubbin; Meehyung Cho; Diane J Plotkin; Yale B Mitchel
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Clinical cardiology 2003;26(1):18-24.
2002: Andrew M Tonkin; Carlos A Dujovne
Further evidence of the need to establish treatment safety as well as efficacy in randomized controlled trials.
Current opinion in lipidology 2002;13(6):591-3.
2002: Carlos A Dujovne; Mark P Ettinger; J Frederick McNeer; Leslie Lipka; LeBeaut Pierre Alexandre; Ramachandran Suresh; Bo Yang; Enrico Veltri
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.
The American journal of cardiology 2002;90(10):1092-7.
2002: Harold E Bays; Carlos A Dujovne
Anti-obesity drug development.
Expert opinion on investigational drugs 2002;11(9):1189-204.
2002: Carlos A Dujovne
Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".
The American journal of cardiology 2002;89(12):1411-3.
2002: Harold E Bays; Carlos A Dujovne
Pharmacotherapy of obesity: currently marketed and upcoming agents.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2002;2(4):245-53.
2001: Carlos A Dujovne; A M Tonkin
Ethical, medical and legal issues for the use of placebos in future lipid intervention trials.
Current opinion in lipidology 2001;12(6):599-600.
2001: Jonathan L Isaacsohn; William Insull; Evan Stein; Peter O Kwiterovich; M A Patrick; R Brazg; Carlos A Dujovne; M Shan; E Shugrue-Crowley; S Ripa; R Tota
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.
Clinical cardiology 2001;24(9 Suppl):IV1-9.
2001: Carlos A Dujovne; J H Zavoral; ED Rowe; CM Mendel
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
American heart journal 2001;142(3):489-97.
2001: Harold E Bays; P B Moore; M A Drehobl; S Rosenblatt; P D Toth; Carlos A Dujovne; Robert H Knopp; Leslie Lipka; LeBeaut Pierre Alexandre; Bo Yang; Lillian Mellars; C Cuffie-Jackson; Enrico Veltri
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.
Clinical therapeutics 2001;23(8):1209-30.
2001: William Insull; Michael J Koren; Jean Davignon; D Sprecher; Helmut Schrott; L M Keilson; A S Brown; Carlos A Dujovne; Michael H Davidson; Richard McLain; Therese Heinonen
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Atherosclerosis 2001;157(1):137-44.
2001: Carlos A Dujovne; Harold E Bays; Michael H Davidson; Robert Knopp; Donald B Hunninghake; E A Stein; A C Goldberg; P Jones; Leslie Lipka; C Cuffie-Jackson
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
Journal of clinical pharmacology 2001;41(1):70-8.
2000: Carlos A Dujovne; Robert Knopp; Peter O Kwiterovich; Donald B Hunninghake; T A McBride; M Poland
Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.
Mayo Clinic proceedings. Mayo Clinic 2000;75(11):1124-32.
2000: Michael H Davidson; Evan A Stein; Donald B Hunninghake; Leiv Ose; Carlos A Dujovne; William Insull; Marcelo C Bertolami; Stuart R Weiss; John J P Kastelein; Russell S Scott; S Campodónico; Ivan D Escobar; Helmut Schrott; Harold E Bays; Michael Stepanavage; M Wu; A C Tate; MR Melino; Debra Kush; Michele Mercuri; Yale B Mitchel
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2000;10(5):253-62.
2000: Evan Stein; Diane J Plotkin; Harold E Bays; Michael Davidson; Carlos A Dujovne; Stanley G Korenman; Michael Stepanavage; Michele Mercuri
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
The American journal of cardiology 2000;86(4):406-11.
2000: John J P Kastelein; Jonathan L Isaacsohn; Leiv Ose; Donald B Hunninghake; J Frohlich; Michael H Davidson; R Habib; Carlos A Dujovne; John R Crouse; M Liu; MR Melino; L O'Grady; Michele Mercuri; Yale B Mitchel
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
The American journal of cardiology 2000;86(2):221-3.
2000: William Insull; Jonathan L Isaacsohn; Peter O Kwiterovich; P Ra; R Brazg; Carlos A Dujovne; M Shan; E Shugrue-Crowley; S Ripa; R Tota
Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
The Journal of international medical research 2000;28(2):47-68.
2000: K D Pfuetze; Carlos A Dujovne
Probucol.
Current atherosclerosis reports 2000;2(1):47-57.
1999: Carlos A Dujovne
Middle-aged men at high risk of cardiovascular disease: the West of Scotland Coronary Prevention Study.
The American journal of medicine 1999;107(2A):34S-35S.
1999: J R Guyton; Carlos A Dujovne; D Roger Illingworth
Dual hepatic metabolism of cerivastatin--clarifications.
The American journal of cardiology 1999;84(4):497.
1999: R H Knopp; HR Superko; M Davidson; William Insull; Carlos A Dujovne; Peter O Kwiterovich; J H Zavoral; K Graham; R R O'Connor; D A Edelman
Long-term blood cholesterol-lowering effects of a dietary fiber supplement.
American journal of preventive medicine 1999;17(1):18-23.
1999: Harold E Bays; Carlos A Dujovne
Lipid-altering drugs in development.
Drugs in R&D 1999;1(6):463-9.
1999: Evan A Stein; D Roger Illingworth; Peter O Kwiterovich; C A Liacouras; M A Siimes; Marc Jacobson; T G Brewster; P Hopkins; M Davidson; K Graham; F Arensman; Robert H Knopp; Carlos A Dujovne; C L Williams; Jonathan L Isaacsohn; CA Jacobsen; PM Laskarzewski; S Ames; GJ Gormley
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;281(2):137-44.
1998: Harold E Bays; Carlos A Dujovne
Drug interactions of lipid-altering drugs.
Drug safety : an international journal of medical toxicology and drug experience 1998;19(5):355-71.
1998: Evan A Stein; Michael H Davidson; Adrian S Dobs; Helmut Schrott; Carlos A Dujovne; Harold E Bays; Stuart R Weiss; MR Melino; Michael Stepanavage; Yale B Mitchel
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
The American journal of cardiology 1998;82(3):311-6.
1997: Michael H Davidson; Evan A Stein; Carlos A Dujovne; Donald B Hunninghake; Stuart R Weiss; Robert H Knopp; D Roger Illingworth; Yale B Mitchel; MR Melino; R V Zupkis; MR Dobrinska; R D Amin; Jonathan A Tobert
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
The American journal of cardiology 1997;79(1):38-42.
1995: William S Harris; S J Held; Carlos A Dujovne
Comparison of two scoring systems used to monitor diets in outpatient clinical trials.
Journal of cardiovascular risk 1995;2(4):359-65.
1995: W Insull; Michael H Davidson; D M Demke; Carlos A Dujovne; S M Eckert; D Ginsberg; A C Goldberg; H N Hodis; T A Hughes; J P Kane
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
Atherosclerosis 1995;112(2):223-35.
1995: Helmut Schrott; Evan A Stein; Carlos A Dujovne; Michael H Davidson; G B Goris; T H Oliphant; J C Phillips; G G Shawaryn
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
The American journal of cardiology 1995;75(1):34-9.
1994: W Insull; D Black; Carlos A Dujovne; J D Hosking; Donald B Hunninghake; L Keilson; R Knopp; J McKenney; E Stein; A J Troendle
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Archives of internal medicine 1994;154(21):2449-55.
1994: R H Bradford; C L Shear; A N Chremos; Carlos A Dujovne; F A Franklin; R B Grillo; J Higgins; A Langendorfer; D T Nash; James L Pool
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.
The American journal of cardiology 1994;74(7):667-73.
1994: A Lozada; Carlos A Dujovne
Drug interactions with fibric acids.
Pharmacology & therapeutics 1994;63(2):163-76.
1994: D Roger Illingworth; Evan A Stein; Yale B Mitchel; Carlos A Dujovne; P H Frost; R H Knopp; P Tun; R V Zupkis; R A Greguski
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Archives of internal medicine 1994;154(14):1586-95.
1994: Carlos A Dujovne; William S Harris; L L Gerrond; J Fan; F Muzio
Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia.
The American journal of cardiology 1994;74(1):38-42.
1994: Carlos A Dujovne; Michael H Davidson
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
The American journal of medicine 1994;96(6A):37S-40S.
1994: Harold E Bays; Carlos A Dujovne
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 1994;43():9-41.
1993: Carlos A Dujovne; J Eff; L Ferraro; R J Goldstein; A M Gotto; W D Hall; William S Harris; S J Held; A Herd; Donald B Hunninghake
Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects.
The American journal of cardiology 1993;72(15):1131-6.
1993: Harold E Bays; Carlos A Dujovne; J B Mays
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease.
The Journal of the Kentucky Medical Association 1993;91(11):498-500.
1993: Donald B Hunninghake; Evan A Stein; Carlos A Dujovne; W S Harris; E B Feldman; V T Miller; Jonathan A Tobert; P M Laskarzewski; E Quiter; J Held
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia.
The New England journal of medicine 1993;328(17):1213-9.
1992: Harold E Bays; Carlos A Dujovne; A M Lansing
Drug treatment of dyslipidemias: practical guidelines for the primary care physician.
Heart disease and stroke : a journal for primary care physicians 1992;1(6):357-65.
1992: Harold E Bays; Carlos A Dujovne
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority.
Postgraduate medicine 1992;91(5):162-4, 167-8, 171-2 passim.
1992: James L Pool; C L Shear; M Downton; H Schnaper; S Stinnett; Carlos A Dujovne; R H Bradford; A N Chremos
Lovastatin and coadministered antihypertensive/cardiovascular agents.
Hypertension 1992;19(3):242-8.
1991: R H Bradford; C L Shear; A N Chremos; F A Franklin; D T Nash; D P Hurley; Carlos A Dujovne; James L Pool; H Schnaper; M Hesney
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia.
The American journal of medicine 1991;91(1B):18S-24S.
1991: Carlos A Dujovne; A N Chremos; James L Pool; H Schnaper; R H Bradford; C L Shear; J Higgins; M Downton; F A Franklin; D T Nash
Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.
The American journal of medicine 1991;91(1B):25S-30S.
1991: William S Harris; Sheryl L Windsor; Carlos A Dujovne
Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months.
Journal of the American College of Nutrition 1991;10(3):220-7.
1991: R H Bradford; C L Shear; A N Chremos; Carlos A Dujovne; M Downton; F A Franklin; Lawrence Gould; M Hesney; J Higgins; D P Hurley
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.
Archives of internal medicine 1991;151(1):43-9.
1990: R H Bradford; C L Shear; A N Chremos; Carlos A Dujovne; F A Franklin; M Hesney; J Higgins; A Langendörfer; James L Pool; H Schnaper
Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.
The American journal of cardiology 1990;66(8):44B-55B.
1990: Carlos A Dujovne; W S Harris
Variabilities in serum lipid measurements. Do they impede proper diagnosis and treatment of dyslipidemia?
Archives of internal medicine 1990;150(8):1583-5.
1990: William S Harris; Carlos A Dujovne; K von Bergmann; J Neal; J Akester; Sheryl L Windsor; D Greene; Z Look
Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans.
Clinical pharmacology and therapeutics 1990;48(2):189-94.
1990: William S Harris; S Silveira; Carlos A Dujovne
The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man.
Thrombosis research 1990;57(4):517-26.
1988: William S Harris; M L Zucker; Carlos A Dujovne
Omega-3 fatty acids in hypertriglyceridemic patients: triglycerides vs methyl esters.
The American journal of clinical nutrition 1988;48(4):992-7.
1988: William S Harris; Carlos A Dujovne; M Zucker; B Johnson
Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial.
Annals of internal medicine 1988;109(6):465-70.
1988: M L Zucker; D S Bilyeu; G M Helmkamp; William S Harris; Carlos A Dujovne
Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects.
Atherosclerosis 1988;73(1):13-22.
1987: Robert H Knopp; W Virgil Brown; Carlos A Dujovne; J W Farquhar; E B Feldman; A C Goldberg; S M Grundy; N L Lasser; M J Mellies; R H Palmer
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
The American journal of medicine 1987;83(5B):50-9.
1986: W Virgil Brown; Carlos A Dujovne; J W Farquhar; E B Feldman; S M Grundy; Robert H Knopp; N L Lasser; M J Mellies; R H Palmer; P Samuel
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
Arteriosclerosis (Dallas, Tex.) 1986;6(6):670-8.
1986: Carlos A Dujovne; P Krehbiel; S B Chernoff
Controlled studies of the efficacy and safety of combined probucol-colestipol therapy.
The American journal of cardiology 1986;57(16):36H-42H.
1986: M L Zucker; C Trowbridge; J Woodroof; S B Chernoff; L Reynoso; Carlos A Dujovne
Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects.
Archives of internal medicine 1986;146(5):921-5.
1986: M L Zucker; C Trowbridge; P Krehbiel; B Jackson; S B Chernoff; Carlos A Dujovne
Platelet function in hypercholesterolemics before and after hypolipidemic drug therapy.
Haemostasis 1986;16(1):57-64.
1984: Carlos A Dujovne; S DeCoursey; P Krehbiel; B Jackson; S Chernoff
Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol.
Clinical pharmacology and therapeutics 1984;36(2):157-62.
1984: Carlos A Dujovne; S B Chernoff; P Krehbiel; B Jackson; S DeCoursey; H Taylor
Low-dose colestipol plus probucol for hypercholesterolemia.
The American journal of cardiology 1984;53(11):1514-8.
1984: Carlos A Dujovne; P Krehbiel; S Decoursey; B Jackson; S B Chernoff; A Pitterman; M Garty
Probucol with colestipol in the treatment of hypercholesterolemia.
Annals of internal medicine 1984;100(4):477-82.
1984: Carlos A Dujovne; F Atkins; B Wong; S DeCoursey; P Krehbiel; S B Chernoff
Electrocardiographic effects of probucol. A controlled prospective clinical trial.
European journal of clinical pharmacology 1984;26(6):735-9.
1983: M L Zucker; J Woodroof; P Krehbiel; S DeCoursey; B Jackson; Carlos A Dujovne
The effect of variable fat diets and cholesterol-lowering drugs on Antithrombin III levels in hyperlipoproteinemic and normal subjects.
Thrombosis research 1983;30(6):661-9.
1983: Carlos A Dujovne; A Pitterman; W C Vincek; M R Dobrinska; R O Davies; D E Duggan
Enterohepatic circulation of sulindac and metabolites.
Clinical pharmacology and therapeutics 1983;33(2):172-7.